ICYMI: TNR - Vasculitis: Evolution and Advances This is a replay from the live RNL 2023 meeting and the session on EVOLUTION AND ADVANCES IN VASCULITIS held on March 18, 2023. https://t.co/OAI8NbSNes https://t.co/eDqqV9yZ9d

• https://bit.ly/3BDqAqW

TNF Inhibitors and Acne? A literature review found 47 refractory acne pts Rx w/ TNFi; noting partial improvement (94%) or clearance (40%) & only 6% w/ adverse events. 17 pts had new-onset acne after Rx w/ TNFi for a different inflamm Dx. Odd! https://t.co/duHEIHBMyK https://t.co/br8NQZQE2r

• https://bit.ly/3ocyOmO

The Schwartzman's (Monica and Sergio) discuss being in rheumatology as a family unit. We are so lucky in rheumatology to have many family connections! #RNL2023 @RheumNow https://t.co/hFbeGll2ut https://t.co/dfHnnbpNS8

• https://bit.ly/45bq0OC

Dr. Anisha Dua on Imaging in PMR: - US of shoulders to eval for bursitis can increase specificity - MRI better for pelvic girdle, but expensive - Consider PET if lack of response to steroids, r/o malignancy #RNL2023 @RheumNow https://t.co/tjhGlJPDWZ https://t.co/9h1FwfM0CP

• https://bit.ly/3WflJpm

Dr. Langford's take home for GPA. Remember to consider disease severity (will determine tx,) maintenance tx, and non-medical management including vaccination options for pts. #RNL2023 @RheumNow https://t.co/R6nrz7YXZr https://t.co/UVY0jDUGJ2

• https://bit.ly/3BDoJTa

Avacopan in GPA - non-inferior to prednisone for induction remission - received FDA approval for treatment of severe active GPA in combo with standard therapy and steroids - should be used in newly diagnosed active or relapsing disease @rheumnow #RNL2023 https://t.co/My6M5MGBl1 https://t.co/0aPFUeE55Q

• https://bit.ly/3BAxm0L

How to long for maintenance of GPA? Continue for 24 months, then consider: Relapse history? Organ damage? Toxicity? Patient wishes? Compliance? Family planning? Dr. Langford @RheumNow #RNL2023 https://t.co/tFn2p5DfJV https://t.co/Uu4Fmans40

• https://bit.ly/3MewvHP

U.S. FDA Approves RINVOQ® (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults based on induction studies, U-EXCEED, U-EXCEL,& U-ENDURE maintenance study. This is 7th FDA approval for RINVOQ https://t.co/FypYaTMJxU https://t.co/yilppBv6Ka

• https://bit.ly/43cetwJ

Dr. Carol Langford on GPA treatment Duration of remission maintenance therapy? - at least 2 years, after 2 years, maintenance appropriate in many cases - consider RTX, and other cDMARDs (MTX, MMF, AZA) @RheumNow #RNL2023 https://t.co/gAEo6SudES https://t.co/RGSzXy0vE5

• https://bit.ly/3Im8XQe

Dr. Langford #RNL2023 When to use CYC over RTX for severe GPA induction? - Severe disease with RTX intolerance - Worsening disease despite RTX - RGPN Cr > 4.0, mechanical ventilation? (these were excluded from RAVE trial) @RheumNow https://t.co/AnSAnGP6Oa https://t.co/iHF6tiFvj2

• https://bit.ly/3od8sRH

Carol Langford #RNL2023 Use of CYC + RTX: Not routine upfront, but may be needed for escalating disease Limited data to support initial usage Higher risk of hypogammaglobulinemia, infection, and death @RheumNow https://t.co/DRLf1Zl5bN https://t.co/fSv5ciAklI

• https://bit.ly/45bNEKY

Carol Langford #RNL2023 @RheumNow Rx options for GPA showed by targeted to patient's disease characteristics of severe vs non-severe disease CYC not for non-severe due to toxicity MTX, MMF not for severe disease https://t.co/jw3wq2k7gb https://t.co/y3ck6KuCDj

• https://bit.ly/3MDkn4A

"Highest pre-test probability for GCA is actually: 1) Limb claudication 2) Jaw claudication #RNL2023 @RheumNow https://t.co/Ed52fIcVaI" https://t.co/dA1FlCEU3i

• https://bit.ly/434RYKb

GCA biopsy: When and How Early is best, rec'd in first 2 weeks. Findings can be present at 8 weeks but be less prominent @anisha_dua rec's unilateral imaging in most pts, especially w scalp tenderness on one side >1 cm length #RNL2023 @RheumNow https://t.co/Pn25Qt0WL4 https://t.co/5qROaTbD2w

• https://bit.ly/3OrFx7j